RxDoctor Payments Data

Javier Lopez-De-Arco, MD

Internal Medicine · Kissimmee, FLNPI 1295729986

Payments from drug & device makers

$3,195in general payments, 2019–2025

Across 149 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$555
  • Lilly USA, LLC$355
  • AstraZeneca$349
  • Insulet Corporation$302
  • Boehringer Ingelheim$268
  • Corcept Therapeutics$206
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,184100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,195 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$7,658
Medicare patients
29
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$66,065
JardianceEmpagliflozin39$42,641
OzempicSemaglutide28$42,534
FarxigaDapagliflozin Propanediol16$24,478
XareltoRivaroxaban13$7,487
Omega-3 Acid Ethyl Esters32$2,969
SynthroidLevothyroxine Sodium13$1,749
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,219
Levothyroxine Sodium92$1,029
Atorvastatin Calcium122$827
Famotidine34$790
Ventolin HfaAlbuterol Sulfate11$622
Losartan Potassium55$590
Rosuvastatin Calcium63$532
Bisoprolol Fumarate13$498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$355$66,06538 claims
Boehringer IngelheimJardiance$268$42,64139 claims
Novo NordiskOzempic$555$42,53428 claims
AstraZenecaFarxiga$349$24,47816 claims
AbbVieSynthroid$72$1,74913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$1,02992 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →